Topical niclosamide (ATx201) reduces Staphylococcus aureus colonization and increases Shannon diversity of the skin microbiome in atopic dermatitis patients in a randomized, double-blind, placebo-controlled Phase 2 trial.
Anne WeissEmilie DelavenneCarina MatiasHeimo LaglerDaniel SimonPing LiJon U HansenTeresa Pires Dos SantosBimal JanaPetra PriemelChristine BangertMartin BauerSabine EberlAlina Nussbaumer-PröllZoe Anne ÖsterreicherPeter MatznellerTamara QuintMaria WeberHanne Mørck NielsenThomas RadesHelle Krogh JohansenHenrik WesthWooseong KimEleftherios MylonakisChristian FriisLuca GuardabassiJohn PaceCarina Vingsbo LundbergFatima M'ZaliPascal ButtyNikolaj SørensenHenrik Bjørn NielsenRasmus Toft-KehlerEmma Guttman-YasskyGeorg StinglMarkus ZeitlingerMorten Otto Alexander SommerPublished in: Clinical and translational medicine (2022)
These results suggest that ATx201 could become a new treatment modality as a decolonizing agent.
Keyphrases
- placebo controlled
- double blind
- staphylococcus aureus
- atopic dermatitis
- end stage renal disease
- ejection fraction
- newly diagnosed
- prognostic factors
- phase iii
- randomized controlled trial
- phase ii
- squamous cell carcinoma
- escherichia coli
- methicillin resistant staphylococcus aureus
- phase ii study
- open label
- biofilm formation
- locally advanced